OverviewSuggest Edit

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products.

TypePublic
Founded2001
HQWien, AT
Websitenabriva.com

Latest Updates

Employees (est.) (Jul 2021)72
Revenue (FY, 2020)$5 M(-46%)
Share Price (Jul 2021)$1.1(-3%)
Cybersecurity ratingBMore

Key People/Management at Nabriva Therapeutics

Daniel Burgess

Daniel Burgess

Director
Charles Rowland

Charles Rowland

Director
Ted Schroeder

Ted Schroeder

Chief Executive Officer
Robert Crotty

Robert Crotty

General Counsel
Steven Gelone

Steven Gelone

President & Chief Operating Officer
Jennifer Schranz

Jennifer Schranz

Chief Medical Officer
Show more

Nabriva Therapeutics Office Locations

Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin 1 and Dublin 4
Wien, AT (HQ)
Leberstrasse 20
Dublin 1, IE
25 N Wall Quay, North Wall
Dublin 4, IE
The Sweepstakes, Ballsbridge Park, Merrion Rd
King of Prussia, PA, US
1000 Continental Dr #600
Show all (4)

Nabriva Therapeutics Financials and Metrics

Nabriva Therapeutics Revenue

Nabriva Therapeutics's revenue was reported to be $5.03 m in FY, 2020
USD

Revenue (Q1, 2021)

2.5m

Gross profit (Q1, 2021)

2.5m

Gross profit margin (Q1, 2021), %

97.5%

Net income (Q1, 2021)

(14.0m)

EBIT (Q1, 2021)

(13.4m)

Market capitalization (22-Jul-2021)

56.3m

Closing stock price (22-Jul-2021)

1.1

Cash (31-Mar-2021)

54.8m

EV

9.3m
Nabriva Therapeutics's current market capitalization is $56.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

9.7m9.5m5.0m

Cost of goods sold

70.0k766.0k

Gross profit

9.4m4.3m

Gross profit Margin, %

99%85%
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020Q1, 2021

Revenue

7.6m847.0k461.0k1.7m525.0k6.9m789.0k1.3m2.5m

Cost of goods sold

15.0k8.0k25.0k62.0k

Gross profit

6.9m781.0k1.3m2.5m

Gross profit Margin, %

100%99%98%98%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.8m86.8m102.0m86.0m41.4m

Accounts Receivable

2.7m3.9m

Prepaid Expenses

1.2m1.6m1.2m1.2m5.9m

Inventories

682.0k5.8m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

27.2m20.1m112.2m89.4m75.3m100.3m91.0m58.7m78.1m26.9m49.7m41.1m54.8m

Accounts Receivable

6.5m3.5m3.2m3.4m4.2m

Prepaid Expenses

903.0k1.4m1.5m1.0m1.2m1.2m973.0k1.4m1.2m2.9m3.9m3.8m10.2m

Inventories

162.0k4.2m5.2m5.8m9.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(54.9m)(74.4m)(114.8m)(82.8m)(69.5m)

Depreciation and Amortization

233.0k432.0k510.0k396.0k417.0k

Inventories

(682.0k)(5.1m)

Accounts Payable

(383.0k)2.6m(3.0m)1.3m(1.8m)
Quarterly
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Nabriva Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Zavante Therapeutics IncJuly 25, 2018$124 m

Nabriva Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Nabriva Therapeutics Online and Social Media Presence

Embed Graph

Nabriva Therapeutics News and Updates

Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021

DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial…

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D in China, and Nabriva Therapeutics (NASDAQ: NBRV), a biopharmaceutical company engaged in the…

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chie…

Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Ch…

Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Dani…

Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary …
Show more

Nabriva Therapeutics Blogs

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021 Content Import Thu, 04/29/2021 - 16:08 Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021 April …

Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.

- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa. , April 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the

WEP Clinical Expands Availability Of Xenleta® (Lefamulin) Named Patient Program In Partnership With Nabriva Therapeutics

March 24 at 8:00 AM EDT WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure that physicians can request IV or oral

Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates

Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates Content Import Thu, 03/11/2021 - 16:10 Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates March 11, 2021…

Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021

DUBLIN, Ireland , March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full
Show more

Nabriva Therapeutics Frequently Asked Questions

  • When was Nabriva Therapeutics founded?

    Nabriva Therapeutics was founded in 2001.

  • Who are Nabriva Therapeutics key executives?

    Nabriva Therapeutics's key executives are Daniel Burgess, Charles Rowland and Ted Schroeder.

  • How many employees does Nabriva Therapeutics have?

    Nabriva Therapeutics has 72 employees.

  • What is Nabriva Therapeutics revenue?

    Latest Nabriva Therapeutics annual revenue is $5 m.

  • What is Nabriva Therapeutics revenue per employee?

    Latest Nabriva Therapeutics revenue per employee is $69.8 k.

  • Who are Nabriva Therapeutics competitors?

    Competitors of Nabriva Therapeutics include Laboratorios Bago, Medicago and USV.

  • Where is Nabriva Therapeutics headquarters?

    Nabriva Therapeutics headquarters is located at Leberstrasse 20, Wien.

  • Where are Nabriva Therapeutics offices?

    Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin 1 and Dublin 4.

  • How many offices does Nabriva Therapeutics have?

    Nabriva Therapeutics has 4 offices.